X-PACT Paper Wins SEAAPM 2017 Best Paper Award

Durham, North Carolina, April 4, 2017 – The South Eastern Chapter of the American Association of Physicists in Medicine (SEAAPM) has chosen Immunolight’s paper, X-Ray Psoralen Activated Cancer Therapy to receive it’s 2017’s best paper award.

Immunolight LLC is a biomedical firm leading the way in technologies that transform energy sources. Immunolight technology has the potential to create a dramatic shift in the treatment of cancer. It wasn’t that long ago that the treatments were limited to three options that included chemotherapy, radiation and surgery.

Although there have been improvements in all three areas, cancer, which has devastating effects emotionally, physically and financially, continues to be one of the most grueling diseases that affect us today.

X-PACT, X-ray Psoralen Activated Cancer Therapy is a new approach in the treatment of solid cancer tumors that utilizes psoralen, a potent, natural compound found in foods like celery, figs and citrus fruits. When exposed to UV light, psoralen causes cell death in cancer cells with the potential to induce an immune response against cancer from inside the tumor.

With a team of over thirty scientists, physicians and engineers, led by President Harold Walder, Immunolight is creating a paradigm shift in the treatment of cancer.

Best Paper Award

SEAAPM is a chapter of the American Association of Physicists in Medicine (AAPM), which is the leading organization in medical physics. Founded in 1958, the American Association of Physicists in Medicine (AAPM) promotes the application of physics to medicine and biology, to encourage interest and training as well as to prepare and distribute technical information in medical physics and related fields.

The SEAAPM region includes, North and South Carolina, Alabama, Mississippi, Georgia and Tennessee, with twenty-one regional AAPM Chapters.

The SEAAPM best paper award is open to papers authored by active SEAAPM members.
Nominations are put forth by active chapter members and then voted on by an awards committee.

“Publishing the results of our development activities is an important part of the technology development. We are honored to be presented with the SEAAPM 2017 Best Paper Award.” Immunolight President Harold Walder said.

Previous
Previous

FDA Clearance to Initiate Phase 1 Trial of the X-PACT System in Solid Tumors

Next
Next

Crain’s Detroit Business News Names Immunolight LLC Most Innovative Company of 2016